Cargando…
TP53-Status-Dependent Oncogenic EZH2 Activity in Pancreatic Cancer
SIMPLE SUMMARY: Epigenetic alterations contribute to the aggressiveness and therapy resistance of Pancreatic Ductal Adenocarcinoma (PDAC). However, epigenetic regulators, including Enhancer of Zeste Homolog 2 (EZH2), reveal a strong context-dependent activity. Our study aimed to examine the context-...
Autores principales: | Versemann, Lennart, Patil, Shilpa, Steuber, Benjamin, Zhang, Zhe, Kopp, Waltraut, Krawczyk, Hannah Elisa, Kaulfuß, Silke, Wollnik, Bernd, Ströbel, Philipp, Neesse, Albrecht, Singh, Shiv K., Ellenrieder, Volker, Hessmann, Elisabeth |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9320674/ https://www.ncbi.nlm.nih.gov/pubmed/35884510 http://dx.doi.org/10.3390/cancers14143451 |
Ejemplares similares
-
Chromatin-Independent Interplay of NFATc1 and EZH2 in Pancreatic Cancer
por: Patil, Shilpa, et al.
Publicado: (2021) -
Preclinical Evaluation of 1,2-Diamino-4,5-Dibromobenzene in Genetically Engineered Mouse Models of Pancreatic Cancer
por: Goetze, Robert G., et al.
Publicado: (2019) -
SPARC dependent collagen deposition and gemcitabine delivery in a genetically engineered mouse model of pancreas cancer
por: Ramu, Iswarya, et al.
Publicado: (2019) -
Familial cleft tongue caused by a unique translation initiation codon variant in TP63
por: Schmidt, Julia, et al.
Publicado: (2021) -
Depletion of Macrophages Improves Therapeutic Response to Gemcitabine in Murine Pancreas Cancer
por: Buchholz, Soeren M., et al.
Publicado: (2020)